| Name | NG25 |
| Description | NG25 is a potent dual inhibitor of TAK1 and MAP4K2, with IC50s of 149 nM and 21.7 nM, respectively. |
| Cell Research | Breast cancer cells were seeded in 12-well plates at 2?×?10^3 cells per well, then incubated with Dox alone or Dox with NG25 at indicated concentrations after 72?h and then were cultured in fresh medium without drug.?Two weeks later, cells were fixed and stained with methanol/crystal violet for 10?min, and photographed.?Each experiment was performed in triplicates[1]. |
| In vitro | NG25 sensitizes the breast cancer cells to Dox treatment in vitro. This combination may be an effective and feasible therapeutic option maximizing Dox efficacy and meanwhile minimizing Dox side effects in treating breast cancer[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 16.67 mg/mL (31.01 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.72 mM), Sonication is recommended.
|
| Keywords | NG-25 | NG25 | NG 25 | MAPK Kinase Kinase Kinase | MAP4K2/TAK1 | MAP4K | MAP3K | MAP kinase kinase kinase, MEKK, MAPKKK | Inhibitor | inhibit |
| Inhibitors Related | Sodium lauryl sulfoacetate | Phosphocreatine disodium hydrate | Vemurafenib | SKLB-163 | RV01 | Takinib | Phosphocreatine disodium | RMM-46 | Oleanolic Acid | Selonsertib | Dehydrocostus Lactone | Sodium new houttuyfonate |
| Related Compound Libraries | Apoptosis Compound Library | Reprogramming Compound Library | Target-Focused Phenotypic Screening Library | Anti-Pancreatic Cancer Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Stem Cell Differentiation Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
United States
